Adenocarcinoma of the Body and Tail of the Pancreas;Treatment and Prognosis.
- Author:
Won Ho KIL
1
;
Dae Kyum KIM
;
Sang Ik NOH
;
Jin Seok HEO
;
Jae Hyung NOH
;
Tae Sung SOHN
;
Sung Ho CHOI
;
Jae Won JOH
;
Yong Il KIM
Author Information
1. Department of surgery, Samsung Medical Center, Sungkyunkwan University, College of Medicine.
- Publication Type:Original Article
- Keywords:
Pancreatic neoplasm,Adenocarcinoma;
Prognostic factors
- MeSH:
Adenocarcinoma*;
Diagnosis;
Drug Therapy;
Humans;
Lymph Nodes;
Middle Aged;
Multivariate Analysis;
Neoplasm Metastasis;
Pancreas;
Prognosis*;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2000;4(2):161-168
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Adenocarcinoma arising in the body or tail of the pancreas tends to be metastasized at the time of diagnosis, is mostly in inoperable stage, and poor in prognosis. In this study, we evaluated the adenocarcinoma arising in the body or tail of the pancreas and investigated the prognostic factors and ideal treatment. MATERIAL AND METHODS: We retrospectively analyzed 33 patients who were cytologically or histologically confirmed as adenocarcinoma in the body or tail of the pancreas at Samsung Medical Center from October 1994 to December 1999. RESULTS: The mean age of the patients in the resectable and unresectable groups were 63.4 and 60.6 year-old, respectively. The mean CA19-9 level was higher in unresectable group (5166.2u/ml), compared to the resectable group (964.7u/ml).(p=0.039) In the resectable group, the body was the most common location of the tumor, and in the unresectable patient group, the tail was more prevalent.(p= 0.021) The mean survival time of the resectable group was 15.1months. The univariate analysis of the resectale group showed that the age, sex, lymph node metastasis, chemotheraeutic modalities, radiotherapeutic modalities, and the location of tumor were not significantly related with the prognosis. In unresetable group, the mean survival time was 6.4months. The mean survival time were 3.3 months in patients over 60 year-old and 9.9 months in patients less than 60, showing statistically significant difference.( p=0.007) The mean survival time were 12.2 months and 3.4 months in patients who received the chemotherapy and who did not, respetively.(p=0.004) Evaluating the relationship between the extent of metastasis and survival, the mean survival length of single metastasis was 9.3 months, showing significantly higher survival length compared that of multiple metastasis.(p=0.027) Patient's sex, radiotherapeutic modality and location of the tumor were not significantly related with the prognosis. Multivariate analysis of prognostic factor showed that the patietnt's age (p=0,842), the extent of metastasis( p=0.458), and chemotherapeutic modality (p=0.078) were unrelated with prognosis. CONCLUSION: In adenocarcinoma arising in the body and tail of the pancreas, the CA19-9 level and tumor location could be utilized as indicating factors of the operability of the tumor. Age, sex, lymph node metastasis, and location of the adenocarcinoma are not significantly related with the survival length in both the resectable and unresectable groups. Also, in both groups, the chemotherapeutic and radiotherapeutic modalities were not related with the survival length.
